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An investigation of the antileishmanial properties
of semi-synthetic saponins†
Orlagh Anderson, ‡a Joseph Beckett,‡a Carla C. Briggs,‡a Liam A. Natrass,ab
Charles F. Cranston, a Elizabeth J. Wilkinson,c Jack H. Owen,c
Rhodri Mir Williams,c Angelos Loukaidis,c Marc E. Bouillon, c Deiniol Pritchard,d
Martina Lahmann, c Mark S. Baird d and Paul W. Denny *a
Leishmaniasis is a neglected tropical disease caused by insect-vector borne protozoan parasites of the,
Leishmania species. Whilst infection threatens and affects millions of the global poor, vaccines are absent
and drug therapy limited. Extensive efforts have recently been made to discover new leads from small
molecule synthetic compound libraries held by industry; however, the number of new chemical entities
identified and entering development as anti-leishmanials has been very low. This has led to increased
interest in the possibility of discovering naturally derived compounds with potent antileishmanial activity
which may be developed towards clinical applications. Plant-derived triterpenoid and steroidal saponins
have long been considered as anti-microbials and here we describe an investigation of a library of 137
natural (9) and semi-synthetic saponins (128) for activity against Leishmania mexicana, a causative agent of
cutaneous leishmaniasis. The triterpenoid sapogenin, hederagenin, readily obtained in large quantities from
Hedera helix (common ivy), was converted into a range of 128 derivatives. These semi-synthetic
compounds, as well as saponins isolated from ivy, were examined with a phenotypic screening approach
to identify potent and selective anti-leishmanial hits. This led to the identification of 12 compounds,
including the natural saponin gypsogenin, demonstrating high potency (ED50 < 10.5 μM) against axenic L.
mexicana amastigotes, the mammalian pathogenic form. One of these, hederagenin disuccinate, was
sufficiently non-toxic to the macrophage host cell to facilitate further analyses, selectivity index (SI) > 10.
Whilst this was not active in an infected cell model, the anti-leishmanial properties of hederagenin-
derivatives have been demonstrated, and the possibility of improving the selectivity of natural hederagenin
through chemical modification has been established.
Introduction
Leishmaniasis is one of the 20 neglected tropical diseases
(NTD), and is endemic in over 90 countries, affecting
approximately 12 million people per year, with over one billion
people living at risk of disease.1 Causative Leishmania species
are sand fly borne kinetoplastid protozoan parasites2 with
infection leading to a wide spectrum of disease, from self-
healing but scarring cutaneous leishmaniasis (CL) to fatal
visceral disease (VL). The diversity of disease is dependent on
the parasite species, genetic background and host immunity.3
Driven by elimination efforts in south Asia, the global burden
of VL has decreased substantially in the past decade. However,
in the same time period, CL cases have increased dramatically
(0.7–1.0 million per year) largely due to forced migration in
conflict zones.4 Against this backdrop, no vaccine is available
and treatment relies entirely on a limited number of less than
ideal drugs. Recently, public–private partnerships have seen
industrial scale (>1 000000) compound libraries screened for
anti-leishmanials either phenotypically5,6 or target-based.7 All
these initiatives focused on VL, leaving the most common form
of leishmaniasis, CL, as a neglected NTD. Treatment of CL
largely relies on the pentavalent antimonials – sodium
stibogluconate (Pentostam) and meglumine antimoniate
(Glucantime).8,9 Both drugs have been in clinical use for over
70 years despite their severe side-effects,10 parenteral
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administration,11 and the emergence of drug resistance.12
Diamidine pentamidine13 and amphotericin B (Fungizone)14
are second-line CL drugs, but are similarly associated with
severe side-effects and Leishmania resistance has been observed
under laboratory conditions.15
The severe issues with the drugs used to treat CL demand
the discovery and development of new effective therapies.
Natural products are the basis of traditional ‘folk’ therapies,
including for leishmaniasis.16,17 The active compounds from
these include chalcones,18–21 flavonoids,22,23 alkaloids24 and
terpenoids.25,26 Further, the anti-leishmanial amphotericin B
is a natural product polyene, which was isolated from
Streptomyces nodosus as an antifungal in 1955.27 With
reference to this history, it is logical to revisit the natural
world in the search for much needed anti-leishmanials.28
Saponins are a diverse class of compounds produced by
many plants, and some marine organisms, via the mevalonic
acid pathway. They consist of an aglycone unit (sapogenin)
linked to between one and three carbohydrate moieties.29,30
Depending on the nature of the sapogenin, saponins are
divided into two main classes – triterpenoid and steroidal.
Triterpenoid saponins mainly occur in dicotyledonous
angiosperms and comprise sapogenin moieties of six
isoprene units, usually arranged as five rings, and bear
structurally diverse carbohydrate groups.31 The less varied
and widespread steroidal saponins consist primarily of a five-
ring furostane or a six-ring spirostane skeleton and are
almost exclusively produced by monocotyledonous
angiosperms.32 The structural diversity of saponins is
associated with a wide range of bioactivities. As secondary
metabolites, their role in plants lies primarily in protection
from herbivory and pathogen attack.29 However, saponins
also possess a variety of pharmaceutical properties, from
anti-inflammatory and anti-cancer to vaccine adjuvant
activity.33,34 Several previous studies have identified saponins
with anti-leishmanial activity.35–51
The beneficial effects of extracts from Hedera helix
(common ivy), and in some cases of the discrete saponins
extracted, have been widely reported. These include anti-
inflammatory properties,52–54 anti-asthma activity55,56 and
applications in cough medicines.57 More recently, anti-viral58
and anti-cancer properties20,59 have been reported. Extracts
also show potent anti-fungal properties,60,61 but of particular
interest were the reports of anti-leishmanial saponins
extracted from H. helix.36,43,50,53,62 Extracted and purified
monodesmoside triterpenoid saponins (α-, β- and δ-hederin)
demonstrated activity against both promastigote (insect
stage) and intracellular amastigote (mammalian stage) forms
of both L. tropica and L. infantum.43
The saponins of common ivy are primarily based on a
triterpene skeleton, hederagenin (Fig. 1), in which the
alcohols or the acid are linked to sugars. Base hydrolysis on
isolation of the saponins leads to the removal of the acid-
bound sugars, and acid hydrolysis to the removal of all
sugars. It is possible to isolate large quantities of saponins
from both ivy leaf and fruit,63 based primarily on a single
sapogenin, hederagenin. It is therefore of interest to
determine whether the biological activity of these saponins,
and of hederagenin, can be optimised by simple chemical
modification to provide novel, plant based, solutions for
application in medicine or agriculture. As part of a wider
study of chemically modified saponins, we now describe the
evaluation of the anti-leishmanial effects of 128 semi-
synthetic molecules obtained by modification of the
hederagenin core, together with nine natural product
controls isolated from ivy extracts.
Results and discussion
Compound screening scheme
The library of hederagenin based compounds (137), either
isolated from Hedera helix or synthesised from hederagenin
obtained by extraction and hydrolysis of ivy saponins, were
screened as illustrated in Fig. 2.
All available compounds were subjected to a primary
screen against mammalian stage L. mexicana axenic
amastigotes as described below. These data and the structures
of all compounds tested are provided in the ESI† (Table S1).
Compounds that achieved ≥95% inhibition were taken
forward to a secondary dose response screen which identified
12 highly active compounds for further examination.
Syntheses of compounds taken forward to the toxicity screen
The syntheses of key compounds, those 12 taken through to
toxicity screening (Fig. 2) and not described elsewhere, are
reported here (NMR data in ESI†). The 3,23-O-isopropylidene
protected hederagenin MC-014 (ref. 64) was converted into
the corresponding isocyanate (MC0-15) by a standard
method. This intermediate was converted into a large
number of derivatives (Table S1†). In particular, MC-033 and
MC0-57 were prepared respectively by reaction with L-proline,
or with pyrrolidine followed by hydrolysis (Scheme 1).
Hederagenin methyl ester (1)65 was converted into a series
of 2,23-O-acetal derivatives, including, after ester hydrolysis,
MC-071 (Scheme 2).
Fig. 1 Short-hand structures for hederagenin and its benzyl ester (Bn-
Hed) with relevant numbering.
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Anemoclemosides66 are natural products featuring a
unique open chain sugar moiety, linked to the sapogenin
through an 3,23-O-acetal. However, they share the same
common hederagenin aglycone. In this work a series of
anemoclemosides (Table S1†), including the natural
compound anemoclemoside A,64 were prepared from
hederagenin. The total synthesis of this series of compounds
will be described elsewhere (Lahmann and Bouillon, in
preparation), but many of them have been screened in this
work. The key compound IVL-81 was prepared by
peracetylation of anemoclemoside A (Scheme 3).
With the intention of removing the enzymatically
cleavable glycosidic linkage and thus increase in vivo
stability, a series of C-glycosides was also prepared (Table
S1†). As an alternative, acetal formation via the oxidised
6-position of monosaccharides was also performed. The key
compound IVL-106 was obtained after oxidation67 of the tri-
O-benzyl protected methyl glucoside 2 to the corresponding
aldehyde 3, followed by acetal formation with Bn-Hed (Fig. 1)
to give 4, and subsequent global deprotection (Scheme 4).
While the sugars in most natural saponins occur in their
pyranose form, it was of interest to evaluate a derivative with
a furanosyl residue. Thus, IVL-104 was prepared from an
L-fucose derived propenyl derivative 5 by oxidation,68 prior to
acetal formation with Bn-Hed and global deprotection
(Scheme 5). Since it was not possible to separate the pseudo
anomers at any step of the synthesis, the diastereomeric
mixture was used for biological evaluation.
Gypsogenin (IVL-9) is a saponin closely related to
hederagenin,69 and for this work, it was synthesised from
hederagenin by a protection, oxidation deprotection sequence
(Scheme 6).
Screening of modified and natural saponins
Primary screening. Utilising a 96-well protocol previously
developed to identify anti-leishmanial compounds70 the
hederagenin library was tested in a preliminary screen
against mammalian stage L. mexicana axenic amastigotes at
50 μM in duplicate (137 compounds, Fig. 2 and Table S1†).
An appropriate positive control (amphotericin B) was selected
and the robustness of the platform indicated by Z′ values
Fig. 2 Screening scheme applied to compound library.
Scheme 1 i. DPPA, Et3N, tol, 90 °C, 80%; ii. L-proline, EtOH, reflux to
rt, quant.; iii. pyrrolidine, tol, 88%; iv. HCl(aq), DCM/H2O, quant; v.
AcCl, DMAP, Et3N, tol, 5 °C, 56%.
Scheme 2 i. Methyl 2-formylbenzoate, PTSA (cat), DCM, quant.; ii.
LiOH; THF/MeOH/H2O (4 : 1 : 1), 65 °C, 86%.
Scheme 3 i. Ac2O, pyridine, 90 °C, 95%.
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>0.5.71 58 compounds (Fig. 2 and Table S1,† highlighted
yellow), inhibited amastigote proliferation ≥95%. The
excluded compounds included natural hederagenin (<80%
inhibition; red in Table S1†), with 60 of the derivatives less
active than the cut-off, as well as 19 showing no activity at all
(blue in Table S1†). Several other naturally occurring
saponins were represented in the library. α- and δ-hederins
(IVL-11 and IVL-13), which have been reported to be active
against Leishmania spp were inhibitory above the threshold,
as was gypsogenin (IVL-9) and hederoside B (IVL-12). In
contrast, oleanolic acid (IVL-8), hederoside F (IVL-14) and
hederacoside D (IVL-15) fell below the threshold (Table S1†).
Secondary screening and toxicity testing. The 58 selected
compounds were taken forward into dose response screening
to give the ED50 against axenic L. mexicana as described in the
ESI† (Fig. 2 and Table 1, columns 3 and 4). Ten of these
compounds demonstrated EC50 ≤ 10 μM, the industry
standard for anti-leishmanial development,7 including IVL-9
(gypsogenin). Two additional compounds with ED50 < 10.5 μM
were also retained. Eleven of these twelve compounds
demonstrated μM activity against the Leishmania amastigotes
(ED50 2.3–10.4 μM); however, only MC-033 had sub-μM efficacy,
with an ED50 of 0.9 μM. Subsequently, the 12 hits (green in
Table 1, columns 1–3) were taken forward to cytotoxicity
screening against RAW 267.4 macrophages (Fig. 3 and Table 1,
columns 5 and 6). All compounds with ED50 against host cells
≤10 μM were excluded as toxic as were all those that
demonstrated a selectivity index (SI) with respect to
macrophages and axenic amastigotes ≤10 (red in Table 1).7
This triage process excluded 11 compounds, including the
highly active MC-033 (red in Table 1), leaving only IVL-1
(hederagenin disuccinate) (Fig. 3); axenic amastigote ED50 = 2.3
μM; RAW 267.4 ED50 > 100 μM; SI > 43.5.
Previous analyses of the anti-leishmanial activity of
isolated and purified hederagenins (including α-hederin and
related hederin and hederacoside molecules) demonstrated
that they are membrane disruptors of all life cycle stages of
the parasite, but also exert similar activity against
mammalian cells leading to toxicity.36,50 Similar toxicity
issues have been noted with respect to anti-leishmanial
peptides and peptoids which are both classes of membrane
disrupter.70,72–75 Therefore, the ability to modify hederagenin
to form non-toxic, yet anti-leishmanial, hederagenin
disuccinate (IVL-1; Fig. 3) is an important finding. However,
although the axenic amastigote screen was performed with
the clinically relevant parasite stage, this assay has
limitations. Drug penetration of the host cell is not evaluated,
neither is activity in the phagolysosomal environment in
which the parasite resides.76 Previous studies have reported a
lack of correlation between compounds selected in axenic
form screening and intracellular amastigote assays.77
Therefore, IVL-1 (hederagenin disuccinate) was taken forward
to an infected cell assay (Fig. 2 and Table 1, columns 8 and
9). Unfortunately, while passing all initial screens, IVL-1 was
inactive in the infected cell assay (ED50 > 50 μM), that is
against Leishmania amastigotes within the macrophage host.
Nonetheless, the ability to develop a non-toxic anti-
leishmanial hederagenin-derivative is an important step
forward for further development; medicinal chemistry and/or
pharmaceutics may improve the profile of this compound to
facilitate activity against the most clinically relevant, intra-
cellular form of Leishmania.
Structure activity relationships
To further consider the hederagenin derivatives as possible
anti-leishmanial therapeutics, it is important to understand
the relationship between structure and activity.
In total 137 compounds have been screened for this work.
Although sharing the common hederagenin core, the library
Scheme 4 i. (COCl)2, Et3N, DMSO/DCM, −78 °C, 87%; ii. Bn-Hed,
PTSA (cat), DCM, 78%; iii. PdĲOH)2/C, H2, MeOH/MTBE, 92%.
Scheme 5 i. 1. O3, DCM −75 °C, 2. PPh3, 75%; ii. Bn-Hed, PTSA (cat),
DCM, 95%; iii. PdĲOH)2/C, H2, MeOH/MTBE, 80%.
Scheme 6 i. BnBr, K2CO3, DMF, 25 °C, 75% (S1); ii. TBDPSCl,
imidazole, DCM, 0 °C to rt, quant. (S1); iii. Ac2O, pyridine, DCM, rt to
90 °C, 95%; iv. TBAF/AcOH, THF, 50 °C to 100 °C, 27%; v. TEMPO,
BAIB, DCM, 67%; vi. NaOH, DME/THF/H2O, 25 °C, 83%; vii. Pd(OH)2/C,
H2, MeOH/EtOAc, 80%.
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is diverse and can be broadly divided into 8 subgroups
according to functionalities. These the groups are: the
natural products, including the hederosides (group 1), the
anemoclemosides (2), other 3,23-hederagenin acetals (3), the
hederagenin esters (4), compounds in which both the acid
and the diol are protected (as esters and acetals respectively)
– protected hederagenins (5), the ureas (6), the triacids (7),
and a small number non-classified derivatives, principally
intermediates to the synthesis of other compounds (8).
Representative results for the various groups are summarised
as follows:
1. Natural products. While all semi-synthetic molecules
studied were based on the major sapogenin core of Hedera
helix, hederagenin (IVL-7), 8 other compounds in the library
were natural products. In the primary screen, hederagenin
(IVL-7) inhibited amastigote proliferation below the threshold
Table 1 Further testing of molecules reaching the cut-off in the primary screen. Columns 1 and 2: compound code and class. Columns 3 and 4:
secondary screen, dose response study. AMA ED50 – effective dose to kill 50% of axenic L. mexicana amastigotes. Columns 5 and 6: toxicity study. RAW
ED50 – effective dose to kill 50% of host macrophage (RAW 267.4); column 7: SI – selectivity index, RAW ED50/AMA ED50. Columns 8 and 9: InMAC ED50
– effective dose to kill 50% of amastigotes within macrophage host (RAW 267.4), infective cell assay. 95% CI – 95% confidence interval; ND – not
determined as values too wide. Green – selected compounds. Red – compounds excluded on basis of toxicity
RSC Medicinal Chemistry Research Article
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(95%), whereas many of the modified molecules were active
(inhibition ≥95%; Table S1†). Oleanolic acid (IVL-8), a minor
sapogenin in Hedera helix lacking the C-26 hydroxy group
compared to hederagenin, was also deselected (Table S1†). In
contrast, another minor sapogenin, gypsogenin (IVL-9), was a
selected inhibitor and was carried through the three
screening stages of the study (Fig. 2 and 3 and Table 1). The
aglycone gypsogenin is closely related to α-hederin (IVL-11),
having the primary alcohol at C-26 oxidized to an aldehyde.
The natural ivy saponins α-hederin (IVL-11) and δ-hederin
(IVL-13) both reached the cut-off in the primary analyses
(inhibition ≥95%, Table S1†); however, the ED50 values were
too high (>10 μM) in the secondary dose response screen to
warrant further evaluation (Fig. 2 and Table 1). In the
primary screen (Table S1†), the monodesmoside hederoside
B (IVL-12) was also found to be a good inhibitor (≥95%
inhibition), whilst hederoside F (IVL-14) did not reach this
cut-off and the bidesmosidic hederacoside D (IVL-15) showed
no inhibition at all. The unusual saponin anemoclemoside A
(IVL-78),79 comprised of hederagenin linked to an open chain
sugar (L-arabinose) through a 3,23-O-acetal linkage, showed
full inhibition in the primary screen, but also did not meet
the ED50 cut-off in the secondary dose response screen (Fig. 2
and Table 1).
2. Anemoclemosides. The compound library included 28
anemoclemoside derivatives (Table S1†). All incorporated a
3,23-O-acetal linkage and differed primarily in the
stereochemistry of the monosaccharide building blocks
incorporated during the synthesis. Nine molecules in this
group, all with unprotected sugar residues and thus closely
resembling natural saponins, reached the primary screen
threshold (Fig. 2 and Table S1†). One of these, like
hederagenin (IVL-7), contained the free carboxylic acid group
at C28 (IVL-17), another was a methyl ester (IVL-18). Both of
these met the ED50 cut-off in the secondary dose response
screen (Fig. 2 and Table 1). In contrast, the compounds
incorporating protecting groups on the open-chain sugar and
thus deprived of the possibility of establishing hydrogen-
bonding based interactions, showed little activity (Table S1†).
In light of this, surprisingly, the penta-acetate IVL-81 was a
complete inhibitor (100%) in the primary screen and
exceeded the cut-off in the secondary screen.
3. 3,23-Hederagenin acetals. A third group of 15
compounds in the library incorporated other 3,23-acetals of
hederagenin. Nine were taken through to the secondary
screening (Fig. 2 and Table 1). Acetals of simple aldehydes
were poor inhibitors in the primary screen. However, as seen
for the anemoclemoside derivatives, compounds containing
an acetal linkage terminating in a monosaccharide (‘C-
glycosides’), and thus, closely resembling the natural
saponins, were good inhibitors of parasite proliferation. Two
of these derivatives, IVL-104 and IVL-106, were also active in
the secondary screen (Table 1).
4. Hederagenin esters. Another group of molecules in the
library (19) were simple esters of hederagenin. Whilst 12 of
these were taken forward from the primary screen, none were
sufficiently active in the secondary assay to be considered for
toxicity screening (Fig. 2 and Table 1).
5. Protected hederagenins. Twelve compounds
incorporated both a 3,23-acetal and an ester in C-28. Thus,
these differed from compounds in group 3 by not having a
free carboxylic acid group at C-28, and so had lost a highly
polar group. Only two in this group passed the primary
screen. One of these, IVL-105, linked through an acetal to a
glycoside, did not pass the secondary screen, whilst the other,
MC-071, incorporating a free acid on the acetal protecting
group allowing polar interactions, was taken forward into the
final toxicity screen. Seven of this group showed no activity at
all in the primary screen (Fig. 2 and Table 1).
6. Ureas. The largest group (46 derivatives) in the library
were urea derivatives, produced by conversion of the acid
group of hederagenin into an isocyanate followed by amine
addition. Twenty of these derivatives were taken forward to
the secondary screen (Fig. 2 and Table 1). Two passed the
Fig. 3 Hit compound structures selected from dose response study.
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threshold for further evaluation, and one (MC-033), a proline
derivative incorporating a free acid group, was the most
active molecule in the library (ED50 0.9 μM), but also
demonstrated host toxicity (Table 1).
7. The tri-acids. This subgroup contained only one
member, IVL-1, the disuccinate of hederagenin and
structurally a tri-acid. Whilst not one of the highest ranking
molecules in the primary screen, it passed the secondary
screen threshold and was the molecule that demonstrated the
least toxicity by far (Table 1). As such it was the only molecule
selected for the infected cell assay (Fig. 2 and Table 1).
8. Non-classified derivatives. This group included just
seven compounds, primarily intermediates in the preparation
of other library members. None reached the threshold in the
primary assay (Table 1).
Most of the natural saponins evaluated in this study
reached the cut-off point in the primary screen, however only
gypsogenin (IVL-9) was taken forward following secondary
screening. It is the only aldehyde in the compound library,
which may explain its efficacy, and its toxicity (Table 1). As
observed for other saponins, its bioactivity as an anti-
inflammatory and cytotoxic compound has been associated
with the presence of the carbohydrate component.78
However, gypsogenin has also been demonstrated to trigger
the apoptotic pathway in cancer cells.79 Of the synthetically
modified hederagenins, three types were most active anti-
leishmanial: group 6 – a urethane modification in position C-
28; group 2 – an acid at C-28 and a sugar moiety at C-3 and/
or C-23, to resemble natural monodesmotic saponins; and
group 7, IVL-1, with a terminal acid substituent at each of
these positions.
Saponins are well known to disrupt membranes through
the interaction with sterols.80 As such, the amphiphilicity
and the stereochemistry introduced by saccharide moieties
may be of importance. An overall trend was that removal of
polarity from both sides of the aglycone (the C-3, C-26 and
C-28 positions) reduced the anti-leishmanial efficacy.
Interestingly, the bidesmosidic natural compound
hederacoside D (IVL-15) was inactive, suggesting that a
balanced distribution of polarity over the saponin is
important. While some C-28 esters passed the primary screen
cut-off, only the saponin-like methyl ester (e.g. IVL-18) was
selected after the secondary assay. The C-28 methyl ester
incorporating a carboxylic acid group on the C-3,23 acetal
(MC-071), was also selected. Conversely, reducing position
C-28 to the corresponding alcohol (MC-029) resulted in low
activity (below primary screen threshold). An interesting
group of compounds in this context are the xylose based
anemoclemosides analogues. Whilst the C-28 acids IVL-17
and IVL-75 were carried through to the final screes, then
excluded by virtue of low selectivity (SI 6.7 and 3.0
respectively), the corresponding C-28 alcohol IVL-90 failed at
the secondary assay stage. The C-28 methyl ester IVL-89 was
excluded after primary screening. This demonstrated that the
loss of the acid group in C-28 could not be compensated by
keeping an unprotected sugar unit on the C3, C23 position,
indicating that subtle variations in the structure could be
relevant. There was at least some link between activity and
stereochemistry in that only a minority of the cyclised
compounds derived from xylose (e.g. IVL-106) reached the
primary screen threshold, compared to the glucosyl,
arabinosyl and rhamnosyl derivatives. In general, the
anemoclemosides resemble the natural monodesmosides
such as the α- and δ-hederins, with some added flexibility
due to the open chain presentation of the sugar moiety, and
anti-leishmanial activity is at least partly dependent on
amphiphilicity and the stereochemistry introduced by
saccharide moieties. Against this background, the activity of
IVL-81, in which the sugar was protected as a tetra-acetate, is
surprising and indicated that there could be subtle reasons
for anemoclemoside anti-leishmanial activity.
A large number of the library members (46) contained the
urea unit, a well-established ‘drug-like’ pharmacore, and
most of these were active in the primary screen (Table S1†). It
is interesting to note that the one with the lowest ED50 (MC-
033) was the only example to have a free acid substituent on
the urea (Fig. 3).
Conclusions
Given the paucity of safe and effective therapies for CL, and a
rising number of cases in an increasing geographic area, the
search for novel anti-leishmanials is as urgent as ever.
Reflecting the absence of fully validated and assay formulated
targets in these parasites, the focus has been on phenotypic
screening for new lead compounds.81 Natural product
discovery forms part of this global effort and novel anti-
leishmanials from these sources are discovered almost always
as a result of target-blind screening.16,17,28
Novel triterpenoid saponins isolated from Maesa argentea
leaves whilst active against infective stage L. infantum were
also cytotoxic at a similar range.39 Whilst consideration of
delivery mechanisms may mitigate against toxicity,51 other
triterpenoid saponins have more promising profiles. For
example, maesabalide II, again from isolated Maesa argentea
leaves, demonstrated potent and specific anti-leishmanial (L.
infantum) activity and promising in vivo activity.41,42
Furthermore, triterpenoid saponins isolated from Careya
arborea leaves44 and the lower stem parts of Astragalus
oleifolius48 showed specific activity against infective stage L.
donovani. Together these data indicated that triterpenoid
saponins (including hederagenins) may be a source of drug
leads from leishmaniasis. However, in many cases these
natural products are isolated in small quantities and only
after a significant effort separating them from other
components. In contrast, hederagenin can be readily isolated
from Hedera helix (common ivy) in large quantities and in
this study we utilized a phenotypic screening approach to
identify anti-leishmanial semi-synthetic triterpenoid saponins
based on hederagenin.
The most selective (non-toxic to the mammalian
macrophage host cell) anti-leishmanial compound, IVL-1,
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structurally differs substantially from all other 136
compounds in the library screened. This tri-acid, the
disuccinate of hederagenin, is known to be active in
improving the growth of ruminants,82 and it and its salts
have been reported to have value as anti-depressant drugs.83
It will be of interest therefore to further evaluate the efficacy
of this molecule and examine other di- or tri-acidic species. It
is also of interest to determine whether the presence of three
acid groups have a specific effect on its bioavailability.
However, to facilitate further development IVL-1 must be
developed to show activity against the parasites when they
are residing with the host cell (intra-macrophage). The use of
both liposomal and nano-particle formulations have been
shown to improve efficacy of natural product anti-
leishmanials and it is feasible that either or both of these
approaches may facilitate the uptake of IVL-1 into the
macrophage as well as improving bioavailability.16,84–86
Subsequently, to aid rational development towards the clinic,
an understanding of the mode of action is vital.87–90 Mass
spectrometry-based metabolomics has been applied to
investigate this for both clinical drugs and experimental
natural compounds, although the results of these studies can
be difficult to interpret.28,91
Notably all but one, the natural cyclic peptide
amphotericin B, of the current clinical anti-leishmanials
lacks a well-defined mechanism of action.16,91 Mammalian
cells harbour cholesterol as the primary sterol, in contrast
fungi and Leishmania spp possess ergosterol.91 This
difference is exploited for both anti-fungal and anti-
leishmanial therapy by amphotericin B which selectively
sequesters ergosterol.91 Following this precedent, saponins
are known to disrupt membranes via interaction with
sterols80 and, like amphotericin B, the selective nature of
IVL-1 may be due to the presence of ergosterol rather than
cholesterol in the plasma membrane of Leishmania. This
requires further investigation and, notably, amphotericin B
resistant Leishmania have been selected and demonstrated by
whole genome sequencing to harbour mutations in the
ergosterol biosynthetic pathway.92,93 Similar analyses could,
in future, reveal the mode of action of the highly selective
disuccinate of hederagenin, IVL-1.
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